vesamicol

RN given refers to parent cpd; structure

Also Known As:

2-(4-phenyl-1-piperidinyl)cyclohexanol; 2-(4-phenylpiperidino)cyclohexanol; AH 5183; AH-5183; methylvesamicol; vesamicol hydrochloride; vesamicol hydrochloride, (+,-)-; vesamicol, (+,-)-

Networked: 13 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - vesamicol: 13

Experts

1.	Mori, Hirofumi: 2 articles (11/2009 - 02/2009)
2.	Ogawa, Kazuma: 2 articles (11/2009 - 02/2009)
3.	Shiba, Kazuhiro: 2 articles (11/2009 - 02/2009)
4.	Ichikawa, A: 2 articles (03/2001 - 10/2000)
5.	Ikeda, E: 2 articles (03/2001 - 10/2000)
6.	Kuji, I: 2 articles (03/2001 - 10/2000)
7.	Mori, H: 2 articles (03/2001 - 10/2000)
8.	Shiba, K: 2 articles (03/2001 - 10/2000)
9.	Sumiya, H: 2 articles (03/2001 - 10/2000)
10.	Tonami, N: 2 articles (03/2001 - 10/2000)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 10/01/2000 - "Beta-amyloid protein-infused rats with spatial memory impairment may be useful for the development of new radiolabelled vesamicol analogues for the objective evaluation of Alzheimer's disease." 01/01/1999 - "Also, choline acetyltransferase activity was percentually more reduced than [3H]vesamicol binding in Alzheimer's disease. " 01/01/1990 - "Choline acetyltransferase activity and [3H]vesamicol binding in the temporal cortex of patients with Alzheimer's disease, Parkinson's disease, and rats with basal forebrain lesions." 01/01/1999 - "The binding of all ligands was significantly decreased in all layers of the temporal cortex in Alzheimer's disease, but the [3H]vesamicol binding decreased only half as much as the nicotinic receptors. " 07/01/1996 - "The level of [3H]vesamicol binding to a terminal vesicular acetylcholine transporter is inversely related to the decline in cortical choline acetyltransferase activity in Alzheimer's disease, which may be due to compensatory processes within surviving cholinergic terminals. "
2.	Neurodegenerative Diseases (Neurodegenerative Disease) 04/01/2001 - "To diagnose and investigate neurodegenerative diseases affecting cholinergic neuron density, piperazine derivatives of vesamicol were synthesized and evaluated. " 01/01/2012 - "In addition to their potential as insecticides and nematocides, Spiroindolines represent the only other class of chemical ligands for the vesicular acetylcholine transporter since those based on the discovery of vesamicol over 40 years ago, and as such, have potential to provide more selective tools for PET imaging in the diagnosis of neurodegenerative disease. "
3.	Parkinson Disease (Parkinson's Disease) 01/01/1990 - "Choline acetyltransferase activity and [3H]vesamicol binding in the temporal cortex of patients with Alzheimer's disease, Parkinson's disease, and rats with basal forebrain lesions." 01/01/1990 - "Whereas choline acetyltransferase activity decreased in patients with Alzheimer's or Parkinson's disease indicating loss of cholinergic innervation, the number of binding sites for [3H]vesamicol was the same as or higher than in controls. " 09/18/1990 - "We measured the binding of the vesicular acetylcholine transport blocker [3H]vesamicol (2-[4-phenylpiperidino] cyclohexanol; AH-5183) to autopsied frontal cortex and amygdala of patients from 4 disorders having a marked brain cholinergic reduction, namely Alzheimer's disease, Parkinson's disease with dementia, dominantly inherited olivopontocerebellar atrophy and Down's syndrome. "
4.	Neoplasms (Cancer) 08/17/2022 - "Development of tumor-targeting aza-vesamicol derivatives with high affinity for sigma receptors for cancer theranostics." 11/01/2009 - "Evaluation of radioiodinated vesamicol analogs for sigma receptor imaging in tumor and radionuclide receptor therapy."
5.	Dementia (Dementias) 02/01/2009 - "The potential of (-)-o-[11C]methylvesamicol for diagnosing cholinergic deficit dementia." 09/18/1990 - "We measured the binding of the vesicular acetylcholine transport blocker [3H]vesamicol (2-[4-phenylpiperidino] cyclohexanol; AH-5183) to autopsied frontal cortex and amygdala of patients from 4 disorders having a marked brain cholinergic reduction, namely Alzheimer's disease, Parkinson's disease with dementia, dominantly inherited olivopontocerebellar atrophy and Down's syndrome. "

Related Drugs and Biologics

1.	Cholinergic Agents (Cholinergics)
2.	Choline O-Acetyltransferase (Choline Acetyltransferase)
3.	Vesicular Acetylcholine Transport Proteins (Vesicular Acetylcholine Transporter)
4.	Acetylcholine (Acetylcholine Chloride)
5.	sigma Receptors (sigma Receptor)
6.	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)
7.	Ligands
8.	vesamicol
9.	Amyloid beta-Peptides
10.	Tubocurarine (Tubocurarine Chloride)

Related Therapies and Procedures

1.	Precision Medicine
2.	Therapeutics